[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100520475":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":19,"locations":29,"responsibleParty":46,"collaborators":18,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":18,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":18,"enrollmentInfo":57,"targetDuration":18,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":18,"overallStatus":32,"whyStopped":18,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Glaukos Corporation","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"iStent Infinite","EXPERIMENTAL","iStent Infinite Trabecular Micro-Bypass System",[13],"Device: iStent Infinite",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"DEVICE",[9],null,[20,25],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Dari Parizadeh","CONTACT","949-481-0575","dparizadeh@glaukos.com",{"name":26,"role":22,"phone":27,"phoneExt":18,"email":28},"Kerry Stephens","949-481-8057","kstephens@glaukos.com",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Glaukos Investigator Site","RECRUITING","Cincinnati","Ohio","45242","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-84.51439,39.12711,{"lat":42,"lon":41},[45],{"name":21,"role":22,"phone":18,"phoneExt":18,"email":18},{"type":47,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100520475","glaukos-istent-infinite-trabecular-micro-bypass-system-in-subjects-with-mild-to-moderate-primary-open-angle-glaucoma-100520475",false,"NCT06057051","Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma","A Prospective, Multicenter Study of the Glaukos® iStent Infinite Trabecular Micro-Bypass System Model iS3 in Subjects With Mild to Moderate Primary Open-angle Glaucoma","Inclusion Criteria:\n\n* Diagnosis of primary open-angle glaucoma\n* Phakic or pseudophakic\n* Age 35 years or older\n\nExclusion Criteria:\n\n* Traumatic, uveitic, neovascular, angle-closure glaucoma or\n* glaucoma associated with vascular disorders\n* Active corneal inflammation or edema\n* Retinal disorders not associated with glaucoma","ALL","35 Years",{"count":58,"type":59},245,"ESTIMATED","INTERVENTIONAL",[62],"NA","Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment",[65],"Glaucoma","2023-09-26",{"date":68,"type":69},"2023-09-28","ACTUAL",{"date":71,"type":69},"2023-09-01",{"date":73,"type":59},"2027-08",{"name":5,"class":6},1]